Medigene Starts Phase I/II Study with DC Vaccine to Treat Acute Myeloid Leukaemia (AML)
Advertisement
Medigene AG announced that the company's phase I/II clinical trial with its dendritic cell (DC) vaccine for the treatment of acute myeloid leukaemia (AML) has started. Oslo University Hospital, Norway, the main trial centre, has begun to identify potentially eligible patients for enrollment. The study enables Medigene to evaluate its personalised DC vaccines in its first company-sponsored trial and generate further clinical feasibility and safety data of active immunotherapy, complementing ongoing academic clinical phase I/II and phase II studies.
Study design: Medigene's phase I/II multi-centre, open-label trial will include 20 AML patients after completion of standard chemotherapy to reduce the risk of recurrence of leukaemia by using Medigene's DC vaccines. Patients will be vaccinated for 50 weeks, with a follow-up period of one year or until progression. The primary objective is to prove feasibility and safety of active immunotherapy with Medigene's DCs. Secondary objectives are induction of immune responses, control of minimal residual disease (MRD) and clinical response/time to progression (TTP).
Most read news
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Affinité Instruments - Montréal, Canada
Isentio AS is expanding and opens office in Silicon Valley, USA
Pharminox appoints Scientific Advisory Board

An ultra-stable protein nanowire made by bacteria provides clues to combating climate change
Genzyme Expands its Research and Manufacturing Presence in Massachusetts - Starts Construction of State-of-the-Art Science Building in Framingham

Material loss protects teeth against fatigue failure - Computer simulation shows that the reduction of natural dental wear might be the main cause for widely spread non-carius cervical lesions in our teeth
